Retinal vascular calibre changes after intravitreal bevacizumab or dexamethasone implant treatment for diabetic macular oedema
Sanjeewa S Wickremasinghe, Samantha Fraser-Bell, Elizabeth Alessandrello, Hemal Mehta, Mark C Gillies, Lyndell L Lim
British Journal of Ophthalmology | BMJ PUBLISHING GROUP | Published : 2017
PURPOSE: To compare changes in retinal vascular calibre after 2 years of treatment with intravitreal bevacizumab (BVZ) or dexamethasone implant (DEX) in patients with centre-involving diabetic macular oedema (DMO). METHODS: At baseline, 88 eyes of 61 patients with DMO were recruited in a prospective, multicentre, randomised, single-masked clinical trial. Of these subjects, 22 BVZ-treated (52%) and 22 DEX-treated (48%) eyes of 34 patients (56%) had gradable retinal photographs at both the baseline and 24-month visits. Retinal vascular calibre was measured from digital fundus photographs and summarised as central retinal artery (CRAE) and vein (CRVE) equivalents in all gradable eyes at baselin..View full abstract
This study was funded by a project grant from the National Health and Medical Research Council (NHMRC), which was supplemented by an unrestricted educational grant from Allergan Pharmaceuticals. MCG is a Sydney Medical School Foundation Fellow and is supported by an NHMRC Clinical Fellowship.